GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a well-characterized, nanomolar-potency inhibitor of the NADPH oxidase isoforms Nox1 (Ki = 140 nM) and Nox4 (Ki = 110 nM), reducing ROS production and oxidative stress in vitro and in vivo (APExBIO). It modulates downstream effectors such as Akt/mTOR and NF-κB, impacting inflammation, fibrosis, and cell proliferation (Yang et al., 2025). GKT137831 exhibits efficacy in animal models of pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis at oral doses of 30–60 mg/kg/day. The compound is supplied by APExBIO (SKU B4763), with strict solubility and storage requirements for experimental reproducibility. Its selective inhibition profile supports applications in redox signaling and translational disease research (internal link).

Biological Rationale

NADPH oxidases (NOX) are membrane-bound enzymes responsible for the generation of reactive oxygen species (ROS) in mammalian cells. The NOX1 and NOX4 isoforms are implicated in a spectrum of pathological processes, including vascular remodeling, fibrosis, and metabolic disorders (Yang et al., 2025). ROS produced by Nox1/Nox4 activate signaling pathways that regulate inflammation, proliferation, and extracellular matrix deposition. Dysregulation of these enzymes leads to sustained oxidative stress, a key driver of cellular damage in chronic diseases. GKT137831 is designed to inhibit these isoforms selectively, enabling precise modulation of ROS without the off-target effects associated with less selective antioxidants (see related article). This article extends prior discussions by detailing GKT137831's biochemical selectivity and translational relevance in disease models.

Mechanism of Action of GKT137831

GKT137831 is a small-molecule, non-peptidic inhibitor with high affinity for Nox1 and Nox4. Its inhibitory constants (Ki) are 140 nM for Nox1 and 110 nM for Nox4, as measured in cell-free enzymatic assays at 25°C, pH 7.4 (product page). GKT137831 binds to the catalytic subunit of these oxidases, blocking the transfer of electrons from NADPH to molecular oxygen, thereby attenuating ROS production. This reduction in ROS decreases the activation of redox-sensitive pathways, notably Akt/mTOR and NF-κB. These pathways regulate gene expression involved in cell survival, proliferation, and inflammatory cytokine production (Yang et al., 2025). In vitro, GKT137831 lowers hypoxia-induced hydrogen peroxide (H₂O₂) release in human pulmonary artery endothelial and smooth muscle cells. It also downregulates TGF-β1 and upregulates PPARγ, factors central to fibrogenesis and metabolic homeostasis. In contrast with broad-spectrum antioxidants, GKT137831's selectivity allows targeted inhibition of pathological ROS signaling while maintaining physiological redox processes (see further discussion). This mechanistic clarity distinguishes it from less specific ROS modulators.

Evidence & Benchmarks

• GKT137831 inhibits Nox1 with a Ki of 140 nM and Nox4 with a Ki of 110 nM at 25°C, pH 7.4 (APExBIO, product data).
• In vitro, GKT137831 reduces hypoxia-induced H₂O₂ release in human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs) within 24 hours at concentrations of 0.1–20 μM (Yang et al., 2025).
• Oral administration at 30–60 mg/kg/day in mouse models attenuates chronic hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy (Yang et al., 2025).
• GKT137831 reduces liver fibrosis and diabetes-accelerated atherosclerosis in vivo through inhibition of ROS and modulation of TGF-β1 and PPARγ signaling (APExBIO, product page).
• Solubility is ≥39.5 mg/mL in DMSO and ≥2.96 mg/mL in ethanol (with sonication at 25–37°C); it is insoluble in water (APExBIO, product documentation).
• Downregulation of Akt/mTOR and NF-κB was observed in cellular assays post-GKT137831 treatment, providing a mechanistic link to reduced inflammation and proliferation (Yang et al., 2025).
• Validated translational efficacy in fibrotic, vascular, and metabolic disease models distinguishes GKT137831 from earlier generation inhibitors (internal link).

Applications, Limits & Misconceptions

GKT137831 is widely used in academic and preclinical research on oxidative stress, pulmonary hypertension, fibrosis, and diabetes-associated vascular complications. Its selectivity for Nox1/Nox4 makes it suitable for dissecting the roles of these isoforms in disease models. Applications include:

• Pulmonary vascular remodeling studies in hypoxia-induced mouse models.
• Liver fibrosis attenuation research.
• Investigation of diabetes mellitus-accelerated atherosclerosis.
• Analysis of redox-sensitive signaling pathways (e.g., Akt/mTOR, NF-κB).

This article clarifies prior resources by providing up-to-date quantitative benchmarks and workflow integration guidance, supplementing scenario-focused advice in Practical Solutions for Oxidative Stress Assays with GKT137831.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit all NOX isoforms; it is selective for Nox1 and Nox4 only.
• The compound is insoluble in water; improper solvent use can lead to precipitation and experimental failure.
• Long-term storage of prepared solutions at room temperature leads to degradation; stock solutions should be stored at -20°C and used promptly.
• GKT137831 is not a direct scavenger of ROS; it acts upstream by blocking ROS generation.
• Clinical efficacy in humans is under investigation; most data are from animal and in vitro models.

Workflow Integration & Parameters

GKT137831 (B4763) is available from APExBIO and is supplied as a lyophilized powder. For in vitro work, stock solutions are prepared in DMSO (≥39.5 mg/mL) and diluted to final concentrations of 0.1–20 μM in assay buffer. For in vivo studies, oral doses range from 30–60 mg/kg/day in mouse models. Solubility in ethanol improves with gentle warming and sonication. Water should not be used as a solvent. Incubation times typically span 24 hours for cellular assays. Storage at -20°C is recommended; repeated freeze-thaw cycles and long-term room temperature storage should be avoided (APExBIO). This article updates previous overviews by integrating quantitative solubility and protocol details, referencing guidance from GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research.

Conclusion & Outlook

GKT137831 represents a best-in-class, selective dual Nox1/Nox4 inhibitor for oxidative stress research, with mechanistic clarity and translational relevance. Its nanomolar potency, validated efficacy in multiple disease models, and robust workflow compatibility underpin its value in redox and membrane biology studies. As clinical investigations progress, GKT137831 is poised to inform the next generation of therapeutic strategies targeting ROS-driven pathologies. For product specifications and ordering, visit the GKT137831 product page at APExBIO.